

Our Ref: 142/2020
May 2020

Re: Your request made under the Freedom of Information Act 2000

I have a Freedom of Information request regarding Ophthalmology. Could you kindly provide the answers to the questions mentioned below?

- 1) Within your trust how many **intra-vitreous injections/implants** of each of the following drugs have been used in the four-month period from January to April 2020:

Abicipar pegol	0
Bevacizumab	27
Dexamethasone	20
Ranibizumab	100
Aflibercept	816
Brolucizumab	0
Fluocinolone	2

- 2) If your trust is able to identify **intra-vitreous injections/implants** by eye condition, please provide the number of injections/implants used from January to April 2020, for each of the following conditions:

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Wet Age Related Macular Degeneration (wAMD)

Abicipar pegol
Aflibercept
Becavizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Diabetic Macular Oedema (DMO)

Abicipar pegol
Aflibercept
Becavizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Retinal Vein Occlusion - Central (CRVO)

Abicipar pegol
Aflibercept
Becavizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Retinal Vein Occlusion - Branch (BRVO)

Abicipar pegol
Aflibercept
Becavizumab
Brolucizumab
Dexamethasone
Fluocinolone
Ranibizumab

Our Ref: 142/2020
May 2020

Visual impairment due to choroidal neovascularization secondary to pathologic myopia (mCNV)

Abicipar pegol

Aflibercept

Bevacizumab

Brolucizumab

Dexamethasone

Fluocinolone

Ranibizumab